Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
RANEXA
Generic name / active ingredient
ranolazine prolonged-release tablets
Dosage-form class
Ranolazine prolonged-release tablets: current EU 375/500/750 mg; historical U.S. 500/1000 mg. Swallow the tablet whole and do not crush, break or chew it. Milligram figures from different markets are not a self-conversion or multi-tablet assembly guide.
Route
Oral (prolonged-release tablet exact-product identity field; swallow whole)
Record reviewed
2026-08-30

Copy from the pack in hand

Source-linked reading points

  • Start with ‘prolonged/extended release’: do not crush, break or chew. An unscored tablet is not permission to split by feel, and a shared mg figure across markets does not permit assembling one market's larger strength from another's smaller tablets.
  • RANEXA is a chronic stable-angina dossier, not a rescue substitute for sublingual nitroglycerin such as NITROSTAT. New, different, severe or persistent chest pain, or pain with breathing difficulty, sweating or fainting, requires immediate local emergency care; do not wait for a website or self-add a tablet.
  • Strong CYP3A inhibitors such as clarithromycin, ketoconazole, itraconazole, voriconazole and some HIV protease inhibitors, and inducers such as rifampin, carbamazepine, phenytoin, phenobarbital and St John's wort, are priority review items. Do not try to solve them by self-separating doses by a few hours.
  • Diltiazem, verapamil, fluconazole, erythromycin, ciclosporin and grapefruit can affect ranolazine exposure; digoxin, simvastatin, metformin and other medicines may also need joint review. This site does not decide co-use or dose reduction from two names.

Reviewed presentation examples — compare every field

  • Ranolazine 375 mg per tablet; EU prolonged-release tabletEMA EMEA/H/C/000805 · 375 mg
  • Ranolazine 500 mg per tablet; EU prolonged-release tabletEMA EMEA/H/C/000805 · 500 mg
  • Ranolazine 750 mg per tablet; EU prolonged-release tabletEMA EMEA/H/C/000805 · 750 mg
  • Ranolazine 500 mg per tablet; 60-tablet bottle (historical U.S. brand label)NDC 61958-1001-1
  • Ranolazine 1000 mg per tablet; 60-tablet bottle (historical U.S. brand label)NDC 61958-1002-1

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-30
Source record
5 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image